Stuti J Jaiswal1, Thomas J McCarthy2, Nathan E Wineinger3, Dae Y Kang4, Janet Song3, Solana Garcia3, Christoffel J van Niekerk2, Cathy Y Lu3, Melissa Loeks5, Robert L Owens4. 1. The Scripps Research Institute, La Jolla, Calif; Department of Internal Medicine, Scripps Clinic/Scripps Green Hospital, La Jolla, Calif. Electronic address: jaiswal.stuti@scrippshealth.org. 2. Department of Internal Medicine, Scripps Clinic/Scripps Green Hospital, La Jolla, Calif. 3. The Scripps Research Institute, La Jolla, Calif. 4. Division of Pulmonary, Critical Care & Sleep Medicine, University of California San Diego School of Medicine, La Jolla, Calif. 5. Respironics, Inc., a Philips Healthcare Company, Murrysville, Pa.
Abstract
PURPOSE: Studies suggest that melatonin may prevent delirium, a condition of acute brain dysfunction occurring in 20%-30% of hospitalized older adults that is associated with increased morbidity and mortality. We examined the effect of melatonin on delirium prevention in hospitalized older adults while measuring sleep parameters as a possible underlying mechanism. METHODS: This was a randomized clinical trial measuring the impact of 3 mg of melatonin nightly on incident delirium and both objective and subjective sleep in inpatients age ≥65 years, admitted to internal medicine wards (non-intensive care units). Delirium incidence was measured by bedside nurses using the confusion assessment method. Objective sleep measurements (nighttime sleep duration, total sleep time per 24 hours, and sleep fragmentation as determined by average sleep bout length) were obtained via actigraphy. Subjective sleep quality was measured using the Richards Campbell Sleep Questionnaire. RESULTS:Delirium occurred in 22.2% (8/36) of subjects who received melatonin vs in 9.1% (3/33) who received placebo (P = .19). Melatonin did not significantly change objective or subjective sleep measurements. Nighttime sleep duration and total sleep time did not differ between subjects who became delirious vs those who did not, but delirious subjects had more sleep fragmentation (sleep bout length 7.0 ± 3.0 vs 9.5 ± 5.3 min; P = .03). CONCLUSIONS:Melatonin given as a nightly dose of 3 mg did not prevent delirium in non-intensive care unit hospitalized patients or improve subjective or objective sleep.
RCT Entities:
PURPOSE: Studies suggest that melatonin may prevent delirium, a condition of acute brain dysfunction occurring in 20%-30% of hospitalized older adults that is associated with increased morbidity and mortality. We examined the effect of melatonin on delirium prevention in hospitalized older adults while measuring sleep parameters as a possible underlying mechanism. METHODS: This was a randomized clinical trial measuring the impact of 3 mg of melatonin nightly on incident delirium and both objective and subjective sleep in inpatients age ≥65 years, admitted to internal medicine wards (non-intensive care units). Delirium incidence was measured by bedside nurses using the confusion assessment method. Objective sleep measurements (nighttime sleep duration, total sleep time per 24 hours, and sleep fragmentation as determined by average sleep bout length) were obtained via actigraphy. Subjective sleep quality was measured using the Richards Campbell Sleep Questionnaire. RESULTS:Delirium occurred in 22.2% (8/36) of subjects who received melatonin vs in 9.1% (3/33) who received placebo (P = .19). Melatonin did not significantly change objective or subjective sleep measurements. Nighttime sleep duration and total sleep time did not differ between subjects who became delirious vs those who did not, but delirious subjects had more sleep fragmentation (sleep bout length 7.0 ± 3.0 vs 9.5 ± 5.3 min; P = .03). CONCLUSIONS:Melatonin given as a nightly dose of 3 mg did not prevent delirium in non-intensive care unit hospitalized patients or improve subjective or objective sleep.
Authors: Maarten M van Eijk; Mark van den Boogaard; Rob J van Marum; Paul Benner; Piet Eikelenboom; Marina L Honing; Ben van der Hoven; Janneke Horn; Gerbrand J Izaks; Annette Kalf; Attila Karakus; Ine A Klijn; Michael A Kuiper; Frank-Erik de Leeuw; Tjarda de Man; Roos C van der Mast; Robert-Jan Osse; Sophia E de Rooij; Peter E Spronk; Peter H van der Voort; Willem A van Gool; Arjen J Slooter Journal: Am J Respir Crit Care Med Date: 2011-05-11 Impact factor: 21.405
Authors: Joost Witlox; Lisa S M Eurelings; Jos F M de Jonghe; Kees J Kalisvaart; Piet Eikelenboom; Willem A van Gool Journal: JAMA Date: 2010-07-28 Impact factor: 56.272
Authors: Jordan C Yoder; Trevor C Yuen; Matthew M Churpek; Vineet M Arora; Dana P Edelson Journal: JAMA Intern Med Date: 2013-09-09 Impact factor: 21.873
Authors: Aleksandra Kuczmarska; Long H Ngo; Jamey Guess; Margaret A O'Connor; Laura Branford-White; Kerry Palihnich; Jacqueline Gallagher; Edward R Marcantonio Journal: J Gen Intern Med Date: 2016-03 Impact factor: 5.128
Authors: Catherine Duclos; Marie Dumont; Hélène Blais; Jean Paquet; Elyse Laflamme; Louis de Beaumont; Catherine Wiseman-Hakes; David K Menon; Francis Bernard; Nadia Gosselin Journal: Neurorehabil Neural Repair Date: 2013-12-30 Impact factor: 3.919
Authors: Sapna R Kudchadkar; Othman Aljohani; Jordan Johns; Andrew Leroux; Eman Alsafi; Ebaa Jastaniah; Allan Gottschalk; Nehal J Shata; Ahmad Al-Harbi; Daniel Gergen; Anisha Nadkarni; Ciprian Crainiceanu Journal: J Pediatr Date: 2019-03-15 Impact factor: 4.406
Authors: Bradley Wibrow; F Eduardo Martinez; Erina Myers; Andrew Chapman; Edward Litton; Kwok M Ho; Adrian Regli; David Hawkins; Andrew Ford; Frank M P van Haren; Simon Wyer; Joe McCaffrey; Alan Rashid; Erin Kelty; Kevin Murray; Matthew Anstey Journal: Intensive Care Med Date: 2022-02-27 Impact factor: 17.440
Authors: Judith Sys; Simon Van Cleynenbreugel; Mieke Deschodt; Lorenz Van der Linden; Jos Tournoy Journal: Eur J Clin Pharmacol Date: 2019-12-14 Impact factor: 2.953
Authors: Bradley Wibrow; F Eduardo Martinez; Andrew Ford; Erin Kelty; Kevin Murray; Kwok M Ho; Edward Litton; Erina Myers; Matthew Anstey Journal: Trials Date: 2021-01-05 Impact factor: 2.279
Authors: D Longrois; F Petitjeans; O Simonet; M de Kock; M Belliveau; C Pichot; Th Lieutaud; M Ghignone; L Quintin Journal: Rom J Anaesth Intensive Care Date: 2021-01-04
Authors: Elizabeth Mahanna-Gabrielli; Todd A Miano; John G Augoustides; Cecilia Kim; Joseph E Bavaria; W Andrew Kofke Journal: PLoS One Date: 2018-11-27 Impact factor: 3.240